Methods of prognosis and diagnosis of sepsis
OwnerStuart Blincko, Ingo Curdt +2inventors
InventorsStuart Blincko, Ingo Curdt, Mario Berger, Martin John Llewelyn
Life of this patent
Estimating the term…
Abstract
Provided are methods of diagnosing sepsis in a patient by detecting the presence and/or amount of at least two biomarkers of sepsis or severe sepsis/septic shock in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having sepsis or severe sepsis/septic shock or suspected of having sepsis or severe sepsis/septic shock, or to accurately diagnose a patient having, or suspected of having sepsis or severe sepsis/septic shock. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a sepsis therapy.
Claims46
A method for identifying and treating a subject with sepsis or severe sepsis/septic shock the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PSP in the biological sample to reference levels of sCD25 and PSP;
- (d) identifying the subject as having sepsis or severe sepsis if the levels of sCD25 and PSP in the biological sample are greater than the reference levels of sCD25 and PSP;
- and
- (e) administering a sepsis treatment regimen to the subject identified as having sepsis or severe sepsis.
A method of providing a diagnosis of a subject having sepsis, the method comprising the steps of:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PSP in the biological sample to reference levels of sCD25 and PSP;
- and
- (d) providing a diagnosis of a subject having sepsis or severe sepsis/septic shock if the levels of sCD25 and PSP in the biological sample are greater than the reference levels of sCD25 and PSP.
A method of determining the severity of sepsis in a subject;
- the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PSP in the biological sample to reference levels of sCD25 and PSP;
- and
- (d) correlating the levels of sCD25 and PSP in the biological sample with severity of sepsis in the subject wherein if the levels of sCD25 and PSP in the biological sample are higher than the reference level of sCD25 and PSP in the biological sample, the subject is determined to have increased severity of sepsis.
A method of monitoring the progression of sepsis in a subject, the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the biological sample from the subject;
- and
- (c) correlating the levels of sCD25 and PSP with progression of sepsis in the subject wherein if the levels of sCD25 and PSP are higher as compared to the levels of sCD25 and PSP in an earlier biological sample from the subject, the subject is identified as having progression of sepsis.
A method for the diagnosis, prognosis and/or risk stratification of sepsis or severe sepsis/septic shock in a subject having or suspected of sepsis or severe sepsis/septic shock, the method comprising the step of detecting increased levels of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the subject relative to a control subject not having sepsis or severe sepsis/septic shock.
A method for identifying and treating a subject with sepsis or severe sepsis/septic shock the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and procalcitonin (PCT) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PCT in the biological sample to reference levels of sCD25 and PCT;
- (d) identifying the subject as having sepsis or severe sepsis if the levels of sCD25 and PCT in the biological sample are greater than the reference levels of sCD25 and PCT;
- and
- (e) administering a sepsis treatment regimen to the subject identified as having sepsis or severe sepsis.
A method of providing a diagnosis of a subject having sepsis, the method comprising the steps of:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and procalcitonin (PCT) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PCT in the biological sample to reference levels of sCD25 and PCT;
- and
- (d) providing a diagnosis of a subject having sepsis or severe sepsis/septic shock if the levels of sCD25 and PCT in the biological sample are greater than the reference levels of sCD25 and PCT.
A method of determining the severity of sepsis in a subject;
- the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and procalcitonin (PCT) in the biological sample from the subject;
- (c) comparing the levels of sCD25 and PCT in the biological sample to reference levels of sCD25 and PCT;
- and
- (d) correlating the levels of sCD25 and PCT in the biological sample with severity of sepsis in the subject wherein if the levels of sCD25 and PCT in the biological sample are higher than the reference level of sCD25 and PCT in the biological sample, the subject is determined to have increased severity of sepsis.
A method of monitoring the progression of sepsis in a subject, the method comprising:
- (a) obtaining a biological sample comprising blood from the subject;
- (b) determining the level of soluble CD25 (sCD25) and procalcitonin (PCT) in the biological sample from the subject;
- and
- (c) correlating the levels of sCD25 and PCT with progression of sepsis in the subject wherein if the levels of sCD25 and PCT are higher as compared to the levels of sCD25 and PCT in an earlier biological sample from the subject, the subject is identified as having progression of sepsis.
A method for the diagnosis, prognosis and/or risk stratification of sepsis or severe sepsis/septic shock in a subject having or suspected of sepsis or severe sepsis/septic shock, the method comprising the step of detecting increased levels of soluble CD25 (sCD25) and procalcitonin (PCT) in the subject relative to a control subject not having sepsis or severe sepsis/septic shock.
Dependencies are inferred from the claim text.